Recent health Care

Have a Nice Day

PRODUCTS

RETAXEL (Docetaxel) is used for:

Treatment of locally advanced or metastatic breast cancer
For locally advanced or metastatic non small cell lung cancer after failure of prior platinum-based chemotherapy
Locally advanced squamous cell carcinoma of the head & neck, Hormone refractory metastatic prostate cancer

Generic Name	Strength	Type	Packing	Pack Size
Docetaxel	20 mg	INJ	Vial	0.5 ml
Docetaxel	80 mg	INJ	Vial	2 ml
Docetaxel	120mg	INJ	Vial	3 ml

REPACLI ^® (Paclitaxel) indicated in:

Treatment of patients with metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy
Treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy with anthracyclines unless clinically contraindicated
In non small cell lung cancer
As second line treatment of AIDS - related Kaposi's sarcoma

Generic Name	Strength	Type	Packing	Pack Size
Paclitaxel	100 mg	INJ	Vial	16.7 ml
Paclitaxel	260 mg	INJ	Vial	43.4 ml
Paclitaxel	300mg	INJ	Vial	50 ml

RECITABIN (Gemcitabine) used as :

Treatment of patient with locally advanced (nonrecsectable stage II or III or metastatic (stageIV) advanced carcinoma of the pancreas
In combination with paclitaxel for the first line treatment of patients with metastatic breast cancer after failure of prior anthracycline containing adjuvant therapy
Inoperable, locally advanced (stage IIIA or IIIB) or metastatic non small cell lung cancer, Ovarian cancer

Generic Name	Strength	Type	Packing	Pack Size
Gemcitabine	200 mg	INJ	Lyophilized vial	10 ml
Gemcitabine	1 gm	INJ	Lyophilized vial	50 ml

RERUBICIN ^® (Epirubicin) indicated in:

As a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

Generic Name	Strength	Type	Packing	Pack Size
Epirubicin	10 mg	INJ	Lyophilized Vial	5 ml
Epirubicin	50 mg	INJ	Lyophilized Vial	30 ml
Epirubicin	100 mg	INJ	Lyophilized Vial	50 ml

RETINIB^® (Imatinib) indicated in:

The patients with haematological malignanciesor malignant sarcomas .
Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) and its all 3 phases-Blast Crisis , Accelerated Phase or Chronic Phase. Pediatric Patients with Ph+ CML . Ph+ Acute Lymphoblastic Leukemia
After Interferon-alpha Therapy
Myelodysplastic/ Myeloproliferative Diseases
Aggressive Systemic Mastocytosis (ASM)
Hypereosinophilic Syndrome and/or Chronic Eosinophilic Leukemia
Kit+ Gastrointestinal Stromal Tumors (GIST). Dermatofibrosarcoma Protuberans

Generic Name	Strength	Type	Packing	Pack Size
Imatinib	400 mg	Tab	Child lock HDPE Bottle	1x30

REGEF ^® (Gefitinib) indicated as:

A monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies or RETINIB™ (Gefitinib) may also be used for HNC with Flourouracil hydroxyurea.

Generic Name	Strength	Type	Packing	Pack Size
Gefitinib	250 mg	Tab	Child lock HDPE Bottle	1x30